@article{eabc9ea48c174d33bed08f11ffe87eb9,
title = "New Pharmacogenomics Research Network: An Open Community Catalyzing Research and Translation in Precision Medicine",
abstract = "The goal of pharmacogenomics research is to discover genetic polymorphisms that underlie variation in drug response. Increasingly, pharmacogenomics research involves large numbers of patients and the application of new technologies and methodologies to enable discovery. The Pharmacogenomics Research Network (PGRN) has become a community-driven network of investigators spanning scientific and clinical disciplines. Here, we highlight the activities and types of resources that enable PGRN members to enhance and drive basic and translational research in pharmacogenomics.",
author = "Relling, {M. V.} and Krauss, {R. M.} and Roden, {D. M.} and Klein, {T. E.} and Fowler, {D. M.} and N. Terada and L. Lin and M. Riel-Mehan and Do, {T. P.} and M. Kubo and Yee, {S. W.} and Johnson, {G. T.} and Giacomini, {K. M.}",
note = "Funding Information: Resources for PGRN members are coor dinated by the PGRN-Hub. Major col laborative research resources, which are coordinated by the PGRN-Hub, involve collaborations with RIKEN Integrative Medical Science (IMS), BioBank Japan, and Kaiser Permanente Northern California (KPNC). The PGRN-RIKEN Global Alliance (PGRN-RIKEN) collaboration, which was launched in 2008, represents a large international genomewide association study (GWAS) resource. Over 40 pharma-cogenomic GWAS projects are supported by this mechanism. The PGRN-Hub organizes two PGRN-RIKEN meetings each year to enable submission and review of new proposals for pharmacogenomics GWAS and sequencing.5 Once accepted, the PGRN-RIKEN collaborative projects provide genomewide genotyping or targeted sequencing at RIKEN (http://www. pgrn.org/pgrn-riken.html). Resources provided by KPNC (http://www.pgrn.org/ rpgeh.html) and BioBank Japan (http:// www.pgrn.org/biobank-japan.html) enable multidisciplinary research in pharmacoge-nomics with a focus on multiple ethnic groups. For the KPNC resource, the PGRN member may propose a pilot phar-macogenomics project based on the Research Program in Genes and Environment on Health (RPGEH) resource, which includes 100,000 patients at KPNC with genomewide genotyping and phenotypes from the electronic medical records. This resource is particularly useful for investigators seeking preliminary data or information to enable National Institutes of Health (NIH) research proposals. Similar processes are available for the BioBank Japan, which includes GWAS and phenotype data.6 Publisher Copyright: {\textcopyright} 2017 American Society for Clinical Pharmacology and Therapeutics.",
year = "2017",
month = dec,
doi = "10.1002/cpt.755",
language = "English",
volume = "102",
pages = "897--902",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",
}